3110003A17Rik Inhibitors

The classification of Abracl Inhibitors encompasses a range of chemicals that can indirectly influence the cellular and molecular processes potentially associated with Abracl. This class includes inhibitors of actin polymerization such as Cytochalasin D and Latrunculin A, which disrupt the actin cytoskeleton, potentially affecting any Abracl-related functions tied to actin dynamics. Similarly, compounds like Blebbistatin and ML-7, which inhibit myosin II and myosin light chain kinase (MLCK), respectively, can modify muscle contraction and might thereby impact Abracl's role in muscle cells.

Compounds like Y-27632, which inhibits Rho-associated protein kinase (ROCK), and Jasplakinolide that stabilize actin filaments, can also alter the actin cytoskeleton and possibly the activity of Abracl. Inhibitors of actin nucleation and elongation, such as CK-666 and SMIFH2, which target the Arp2/3 complex and formins, respectively, represent another aspect of this chemical class, as they can perturb actin filament formation and growth. Additionally, BDM, an inhibitor of myosin ATPase, and microtubule affecting agents like colchicine and nocodazole, can disrupt the cytoskeletal dynamics and might indirectly influence Abracl's functions.